Standout Papers

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanc... 2021 2026 2022 2024175
  1. Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma (2021)
    David F. McDermott, Jae‐Lyun Lee et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 5 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

The conneXion between sex and immune responses
2024 Standout
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2024 Standout
2 intermediate papers

Works of Charles Schloss being referenced

Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.
2019
KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC)
2018

Author Peers

Author Last Decade Papers Cites
Charles Schloss 715 635 51 323 65 942
David Pook 592 439 64 292 57 926
Melissa A. Reimers 509 442 48 265 52 872
Gonzalo Recondo 553 616 64 361 52 1.1k
Antonella Palazzo 478 698 28 305 64 1.2k
Michael E. Hurwitz 313 567 36 355 68 1.1k
Xianshu Gao 456 508 85 305 90 1.1k
S-A. Im 435 776 160 320 82 1.1k
Dingwei Ye 597 398 76 486 83 1.1k
Xuezhi Hao 672 700 53 361 112 1.1k
Yota Yasumizu 346 310 104 399 77 879

All Works

Loading papers...

Rankless by CCL
2026